The estimated Net Worth of Remi Barbier is at least $22.4 Million dollars as of 24 May 2023. Mr. Barbier owns over 85,713 units of Cassava Sciences Inc stock worth over $21,372,115 and over the last 9 years he sold SAVA stock worth over $0. In addition, he makes $1,073,230 as Chairman of the Board, President, and Chief Executive Officer at Cassava Sciences Inc.
Sign up
Mr. Barbier SAVA stock SEC Form 4 insiders trading
Remi has made over 9 trades of the Cassava Sciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 85,713 units of SAVA stock worth $1,445,978 on 24 May 2023.
The largest trade he's ever made was buying 100,000 units of Cassava Sciences Inc stock on 31 December 2019 worth over $553,000. On average, Remi trades about 23,873 units every 78 days since 2015. As of 24 May 2023 he still owns at least 782,002 units of Cassava Sciences Inc stock.
You can see the complete history of Mr. Barbier stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Remi Barbier biography
Remi Barbier serves as Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Barbier helped in the growth or founding of Exelixis Inc. and ArQule, Inc., both publicly-traded drug development companies, and EnzyMed, Inc., a chemistry company sold to Albany Molecular Research, Inc. Mr. Barbier is a trustee emeritus of the Carnegie Institute of Washington and the Santa Fe Institute and is on the Advisory Board of the University of California Institute for Quantitative Biosciences and BioVentures LLC, a life science incubator at the University of Arkansas for Medical Sciences. Mr. Barbier received his B.A. from Oberlin College and his M.B.A. from the University of Chicago.
What is the salary of Remi Barbier?
As the Chairman of the Board, President, and Chief Executive Officer of Cassava Sciences Inc, the total compensation of Remi Barbier at Cassava Sciences Inc is $1,073,230. There are no executives at Cassava Sciences Inc getting paid more.
How old is Remi Barbier?
Remi Barbier is 60, he's been the Chairman of the Board, President, and Chief Executive Officer of Cassava Sciences Inc since 1998. There are 7 older and 2 younger executives at Cassava Sciences Inc. The oldest executive at Cassava Sciences Inc is Sanford Robertson, 88, who is the Independent Director.
What's Remi Barbier's mailing address?
Remi's mailing address filed with the SEC is 6801 N CAPITAL OF TEXAS HWY, BLDG 1, SUITE 300, AUSTIN, TX, 78731.
Insiders trading at Cassava Sciences Inc
Over the last 6 years, insiders at Cassava Sciences Inc have traded over $0 worth of Cassava Sciences Inc stock and bought 1,178,376 units worth $9,853,781 . The most active insiders traders include Sanford Robertson, Richard Barry, and Patrick J Md Phd Scannon. On average, Cassava Sciences Inc executives and independent directors trade stock every 45 days with the average trade being worth of $1,235,207. The most recent stock trade was executed by Sanford Robertson on 26 April 2024, trading 69,000 units of SAVA stock currently worth $1,518,000.
What does Cassava Sciences Inc do?
refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.
What does Cassava Sciences Inc's logo look like?
Complete history of Mr. Barbier stock trades at Cassava Sciences Inc
Cassava Sciences Inc executives and stock owners
Cassava Sciences Inc executives and other stock owners filed with the SEC include:
-
Remi Barbier,
Chairman of the Board, President, Chief Executive Officer -
Remi Barbier,
Founder, Chairman, Pres & CEO -
Nadav Friedmann,
Chief Medical and Operating Officer, Director -
Dr. Nadav Friedmann,
Chief Medical Officer & Director -
Eric J. Schoen,
Chief Financial Officer -
Eric Schoen,
Chief Financial Officer -
Sanford Robertson,
Independent Director -
Robert Gussin,
Independent Director -
Patrick Scannon,
Independent Director -
Michael O' Donnell,
Independent Director -
Dr. James W. Kupiec M.D.,
Chief Clinical Devel. Officer -
Dr. Lindsay H. Burns Ph.D.,
Sr. VP of Neuroscience -
Dr. Michael Marsman,
Sr. VP of Regulatory Affairs -
Michael Zamloot,
Sr. VP of Technical Operations -
Dr. George Thornton,
Sr. VP of Technology -
Saira Ramasastry,
Director -
Pierre Gravier,
Director -
Claude Nicaise,
Director -
Robert Christopher Cook,
SVP & General Counsel -
Richard Barry,
Director -
James William Kupiec,
Chief Medical Officer -
Robert Eugene Jr Anderson,
Director